23095-05-8

Basic information

• Product Name: 5-BROMO-2-METHOXYBENZENESULFONYL CHLORIDE
• Synonyms: 5-BROMO-2-METHOXYBENZENESULFONYL CHLORIDE;5-BROMO-2-METHOXYBENZENESULPHONYL CHLORIDE;5-BROMO-2-METHOXYBENZENE-1-SULFONYL CHLORIDE;5-BROMO-2-METHOXYBENZENE-1-SULPHONYL CHLORIDE;BUTTPARK 100\07-65;5-BROMO-2-METHOXYBENZENESULFONYL CHLORIDE 98%;5-Bromo-2-methoxybenzenesulfonyl chloride,98%;4-BroMo-2-(Methyloxy)benzenesulfonyl chloride
• CAS NO: 23095-05-8
• Molecular Formula: C₇H₆BrClO₃S
• Molecular Weight: 285.54
• Product Categories: blocks;Bromides;BuildingBlocks;Organic Building Blocks;Sulfonyl Halides;Sulfur Compounds
• Mol File: 23095-05-8.mol
• Article Data: 8

Chemical Properties

• Melting Point: 115-118 °C(lit.)
• Boiling Point: 362.251 °C at 760 mmHg
• Flash Point: 172.883 °C
• Appearance: white crystalline powder
• Density: 1.717
• Vapor Pressure: 4.08E-05mmHg at 25°C
• Refractive Index: 1.569
• Storage Temp.: 2-8°C
• Sensitive: Moisture Sensitive
• BRN: 3093014
• CAS DataBase Reference: 5-BROMO-2-METHOXYBENZENESULFONYL CHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMO-2-METHOXYBENZENESULFONYL CHLORIDE(23095-05-8)
• EPA Substance Registry System: 5-BROMO-2-METHOXYBENZENESULFONYL CHLORIDE(23095-05-8)

Safety Data

• Hazard Codes: C
• Statements: 34
• Safety Statements: 26-36/37/39-45
• RIDADR: UN 3261 8/PG 2
• WGK Germany: 3
• HazardClass: 8
• PackingGroup: II
• Hazardous Substances Data: 23095-05-8(Hazardous Substances Data)

Usage

Chemical Properties

white crystalline powder

Uses

5-Bromo-2-methoxybenzenesulfonyl chloride may be used in the preparation of the following 1-bromo-3-heteroarylbenzene derivatives:2-(5-bromo-2-methoxyphenyl)benzofuran2-(5-bromo-2-methoxyphenyl)-1-methylpyrrole2-(5-bromo-2-methoxyphenyl)benzoxazoleIt may also be used to synthesize N-(4-ethylbenzoyl)-2-methoxybenzenesulfonamide

General Description

5-Bromo-2-methoxybenzenesulfonyl chloride is a benzenesulfonyl chloride derivative.

InChI:InChI=1/C7H6BrClO3S/c1-12-6-3-2-5(8)4-7(6)13(9,10)11/h2-4H,1H3

Upstream product

• 6358-77-6 5-bromo-2-methoxyaniline 
• 104-92-7 1-bromo-4-methoxy-benzene 

Downstream Products

• 906266-07-7 5-bromo-2-methoxy-N-phenylbenzenesulfonamide 
• 446308-82-3 N-benzyl-5-bromo-2-methoxybenzenesulfonamide 
• 90531-99-0 4-bromo-1-methoxy-2-(methylsulfonyl)benzene 
• 1421747-02-5 C₁₄H₁₅NO₃S 
• 1415724-53-6 C₁₇H₁₄BrF₂N₃O₃S 
• 1415724-52-5 C₁₇H₁₆BrN₃O₃S 
• 1363593-73-0 tert-butyl 8-[3-(5-methyl-1,2,4-oxadiazol-3-yl)phenoxy]-3,4-dihydro-2H-5,1,2-benzoxathiazepine-2-carboxylate 1,1-dioxide 

Relevant articles and documents

Design, synthesis, and biological activity evaluation of a series of novel sulfonamide derivatives as BRD4 inhibitors against acute myeloid leukemia

Accumulating researches have contributed much effect to discover novel chemotherapeutic drug for leukemia with expeditious curative effect, of which bromodomain-containing protein 4 (BRD4) inhibitor is considered as a eutherapeutic drug which has presented efficient cell proliferation suppression effect. In this study, we disclosed a series of phenylisoxazole sulfonamide derivatives as potent BRD4 inhibitors. Especially, compound 58 exhibited robust inhibitory potency toward BRD4-BD1 and BRD4-BD2 with IC50 values of 70 and 140 nM, respectively. In addition, compound 58 significantly suppressed cell proliferation of leukemia cell lines HL-60 and MV4-11 with IC50 values of 1.21 and 0.15 μM. In-depth study of the biological mechanism of compound 58 exerted its tumor suppression effect via down-regulating the level of oncogene c-myc. Moreover, in vivo pharmacokinetics (PK) study was conducted and the results demonstrated better pharmacokinetics features versus (+)-JQ1. In summary, our study discovers that compound 58 represents as a novel BRD4 inhibitor for further investigation in development of leukemia inhibitor with potentiality.

Discovery of 5-((5-chloro-2-methoxyphenyl)sulfonamido)nicotinamide (SBI-425), a potent and orally bioavailable tissue-nonspecific alkaline phosphatase (TNAP) inhibitor

Tissue-nonspecific alkaline phosphatase (TNAP) is an ectoenzyme crucial for bone matrix mineralization via its ability to hydrolyze extracellular inorganic pyrophosphate (ePPi), a potent mineralization inhibitor, to phosphate (Pi). B

1,3,5-TRIAZINE-2-AMINE DERIVATIVES, PREPARATION THEREOF AND DIAGNOSTIC AND THERAPEUTIC USE THEREOF

The present invention relates to compounds corresponding to formula (I) in which: - R1 represents a substituted phenyl; - R2 represents: - a substituted phenyl; - a heteroaromatic group, the said group being unsubstituted or substituted one or more times; - R3 represents a group Alk; - R4 represents a hydrogen atom or a (C1-C4)alkyl; - R5 represents a hydrogen atom, a (C3-C6)cycloalkyl or a (C1-C4)alkyl-O-Alk; - or alternatively R4 and R5, together with the nitrogen atom to which they are attached, constitute a heterocyclic radical chosen from: azetidin-1-yl, pyrrolidin-1-yl, piperid-1-yl, morpholin-4-yl; - R6 represents a group -COOAlk, a group -CONH2 or a group -NHSO2 Alk; - Alk represents a (C1-C4)alkyl, which is unsubstituted or substituted one or more times with a halogen atom; in the form of the base or of an acid-addition salt. Preparation process and diagnostic and therapeutic use